Enfusion (ENFN)
(Delayed Data from NYSE)
$9.42 USD
+0.12 (1.29%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $9.41 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth B Momentum C VGM
Income Statements
Fiscal Year end for Enfusion, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 175 | 150 | 112 | 80 | 59 |
Cost Of Goods | 58 | 47 | 32 | 21 | 17 |
Gross Profit | 117 | 103 | 80 | 58 | 42 |
Selling & Adminstrative & Depr. & Amort Expenses | 105 | 115 | 356 | 52 | 28 |
Income After Depreciation & Amortization | 12 | -12 | -276 | 6 | 14 |
Non-Operating Income | -2 | -1 | -1 | 0 | 0 |
Interest Expense | -2 | 0 | 5 | 2 | 1 |
Pretax Income | 11 | -12 | -282 | 4 | 13 |
Income Taxes | 2 | 1 | 1 | 0 | 0 |
Minority Interest | 3 | -6 | -124 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 9 | -13 | -282 | 4 | 13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 6 | -8 | -158 | 4 | 13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 22 | -6 | -272 | 8 | 15 |
Depreciation & Amortization (Cash Flow) | 10 | 6 | 4 | 2 | 1 |
Income After Depreciation & Amortization | 12 | -12 | -276 | 6 | 14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 129.43 | 85.39 | 83.17 | NA | NA |
Diluted EPS Before Non-Recurring Items | 0.09 | -0.10 | 0.55 | NA | NA |
Diluted Net EPS (GAAP) | 0.07 | -0.10 | -2.26 | NA | NA |
Fiscal Year end for Enfusion, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 46.49 | 44.36 | 42.72 | 40.97 |
Cost Of Goods | NA | 15.62 | 14.51 | 14.21 | 13.30 |
Gross Profit | NA | 30.86 | 29.85 | 28.51 | 27.67 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 28.73 | 27.16 | 26.06 | 22.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.13 | 2.69 | 2.45 | 4.68 |
Non-Operating Income | NA | -1.60 | 0.34 | -1.26 | 0.41 |
Interest Expense | NA | -1.64 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 2.18 | 3.03 | 1.19 | 5.09 |
Income Taxes | NA | 1.28 | 0.37 | 0.19 | 0.40 |
Minority Interest | NA | 0.28 | 0.83 | 0.37 | 1.75 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 0.90 | 2.66 | 1.00 | 4.69 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 0.62 | 1.83 | 0.63 | 2.95 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 127.77 | 127.84 | 129.86 | 132.35 |
Diluted EPS Before Non-Recurring Items | NA | 0.01 | 0.02 | 0.02 | 0.04 |
Diluted Net EPS (GAAP) | NA | 0.01 | 0.02 | 0.01 | 0.04 |